| P50 | author | Seong Soo A An | Q87002891 |
| P2093 | author name string | Yeong Seon Lee | |
| | Jiwon Choi | |
| | Kyoung Tai No | |
| | Jeongmin Lee | |
| | Ran Noh | |
| | Jae Wook Hyeon | |
| | Sol Moe Lee | |
| P2860 | cites work | Prion Protein Biology | Q21972822 |
| | Hot spots in prion protein for pathogenic conversion | Q24670553 |
| | Re-assessment of PrP(Sc) distribution in sporadic and variant CJD | Q28534501 |
| | Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. | Q30373361 |
| | New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products | Q31156724 |
| | Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance | Q33225766 |
| | Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays | Q33769767 |
| | Diphenylpyrazole-derived compounds increase survival time of mice after prion infection. | Q33957528 |
| | Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones | Q34307103 |
| | Cell culture models of transmissible spongiform encephalopathies | Q34444634 |
| | Molecular biology of prion diseases | Q34534878 |
| | Strain specificity and drug resistance in anti-prion therapy. | Q34995352 |
| | Characteristic CSF prion seeding efficiency in humans with prion diseases | Q35024691 |
| | Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivo | Q35087492 |
| | Therapeutic approaches to prion diseases. | Q35122351 |
| | Administration of substances to laboratory animals: routes of administration and factors to consider. | Q35295915 |
| | Approaches to prophylaxis and therapy | Q35549027 |
| | Prion diseases--close to effective therapy? | Q35906120 |
| | Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches | Q36139197 |
| | Anti-Prion Screening for Acridine, Dextran, and Tannic Acid using Real Time-Quaking Induced Conversion: A Comparison with PrPSc-Infected Cell Screening | Q36251365 |
| | Resistance of the scrapie agent to inactivation by psoralens. | Q54498167 |
| | In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrPC to PrPSc | Q57014255 |
| | Insulin-like Growth Factor-1 Receptor Dictates Beneficial Effects of Treadmill Training by Regulating Survival and Migration of Neural Stem Cell Grafts in the Injured Spinal Cord | Q60927515 |
| | Repeated suppression of Creutzfeldt-Jakob disease with vidarabine | Q72533012 |
| | Memantine Attenuates Salicylate-induced Tinnitus Possibly by Reducing NR2B Expression in Auditory Cortex of Rat | Q93175289 |
| | A systematic review of prion therapeutics in experimental models | Q36525632 |
| | Cell models of prion infection | Q37029479 |
| | Therapies for human prion diseases | Q37199225 |
| | Insights from Therapeutic Studies for PrP Prion Disease | Q39005891 |
| | Developing Therapeutics for PrP Prion Diseases | Q39092621 |
| | Dysfunction of the PI3K-Akt-GSK-3 pathway is a common feature in cell culture and in vivo models of prion disease. | Q39143238 |
| | Characterization of toxicological properties of L-lysine polymers in CD-1 mice | Q39412132 |
| | Self-propagating, protease-resistant, recombinant prion protein conformers with or without in vivo pathogenicity. | Q40136054 |
| | Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation | Q40498670 |
| | Prion diseases and the BSE crisis | Q41607167 |
| | Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene | Q41982232 |
| | Prion Diagnosis: Application of Real-Time Quaking-Induced Conversion | Q43050312 |
| | Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding | Q43171852 |
| | Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. | Q43497178 |
| | Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study | Q44790692 |
| | Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings | Q44965016 |
| | Combined quinacrine and chlorpromazine therapy in fatal familial insomnia | Q45023755 |
| | Pathologic conformations of prion proteins | Q46894080 |
| | Results of quinacrine administration to patients with Creutzfeldt-Jakob disease | Q48087933 |
| | Alpha-synuclein deficiency in the C57BL/6JOlaHsd strain does not modify disease progression in the ME7-model of prion disease | Q48419739 |
| | Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases | Q48446912 |
| | Identification of prion amyloid filaments in scrapie-infected brain | Q48492399 |
| | Identification of a protein that purifies with the scrapie prion | Q48858653 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ggplot2 | Q326489 |
| P433 | issue | 1 | |
| P304 | page(s) | 93-105 | |
| P577 | publication date | 2020-02-01 | |
| P1433 | published in | Experimental neurobiology | Q26842060 |
| P1476 | title | BMD42-2910, a Novel Benzoxazole Derivative, Shows a Potent Anti-prion Activity and Prolongs the Mean Survival in an Animal Model of Prion Disease | |
| P478 | volume | 29 | |